Quantifying the ROI of Integrated CDMO-CRO Models in Drug Development

As development costs climb and project timelines grow tighter, the traditional outsourcing model is showing its limitations. Fragmented coordination between CDMOs, CROs, and clinical supply vendors often leads to delays, inefficiencies, and lost opportunities.

A new analysis by the Tufts Center for the Study of Drug Development (CSDD) provides fresh evidence of how integration drives measurable impact quantifying the financial and operational benefits of a fully connected model.

The findings are striking: companies adopting integrated CDMO-CRO partnerships can achieve up to 113x ROI and realize $62.9 million in projected value for Phase III oncology programs alone.

By aligning manufacturing, clinical, and supply services under one framework, organizations can reduce complexity, improve coordination, and accelerate progress from development to delivery.